Sun Pharmaceutical trades at 41.97x TTM P/E (vs Pharma & Health sector median of 31.4x) with a 29.3% operating margin and ₹10,987 Cr annual net profit.
Spot (₹1,922.10) trades against Put writing anchored at ₹1,800.00 (9,25,050 OI) and Call resistance at ₹1,960.00 (4,18,600 OI).
Promoters hold 52.68% with zero encumbrance. Foreign & Domestic Institutions hold 36.63%.
Combined NSE + BSE Order Book · 5-Level Bid/Ask Microstructure
| Bid Price | Exch | Orders | Qty |
|---|---|---|---|
| ₹1,921.00 | NSE | 2 | 10 |
| ₹1,920.00 | NSE | 5 | 149 |
| ₹1,918.00 | NSE | 2 | 7 |
| ₹1,917.95 | BSE | 1 | 7 |
| ₹1,917.40 | NSE | 1 | 10 |
| Ask Price | Exch | Orders | Qty |
|---|---|---|---|
| ₹1,922.00 | BSE | 4 | 82 |
| ₹1,922.80 | NSE | 2 | 11 |
| ₹1,922.90 | NSE | 1 | 350 |
| ₹1,922.90 | BSE | 1 | 10 |
| ₹1,923.00 | NSE | 8 | 863 |
Annual Financial Performance (Figures in ₹ Crore)
| Line Item (₹ Cr) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue / Sales | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 | 61,631 |
| Operating Expenses | 28,397 | 32,235 | 35,479 | 37,464 | 41,961 | 43,567 |
| Operating Profit (EBIT/EBITDA) | 10,258 | 11,650 | 13,018 | 15,114 | 16,501 | 18,064 |
| Other Income | -3,505 | 459 | 865 | 1,444 | 1,895 | 316 |
| Interest & Depreciation | 2,271 | 2,701 | 2,795 | 2,806 | 3,277 | 3,344 |
| Profit Before Tax (PBT) | 4,481 | 9,408 | 11,088 | 13,752 | 15,119 | 15,037 |
| Net Profit (PAT) | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 | 10,987 |
| Balance Sheet Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| Share Capital + Reserves | 48,011 | 55,995 | 63,667 | 72,218 | 83,570 | 89,280 |
| Total Borrowings (Debt) | 1,290 | 6,886 | 3,274 | 2,362 | 4,627 | 3,241 |
| Total Assets | 69,776 | 80,712 | 85,328 | 91,908 | 1,08,407 | 1,14,838 |
Grounded Factor Decomposition & Institutional Bull vs. Bear Debate
RSI 88.5 · SMA20 ₹1,774.94
PAT ₹10,987 Cr · OPM 29.3%
Support ₹1,800.00 · Max Pain ₹1,800.00
Promoter 52.7% · FII+DII 36.6%
Benchmarked by Market Cap, P/E, P/B, Dividend Yield & 1M Returns
| Company | Price (₹) | M.Cap (Cr) | P/E (x) | P/B (x) | Div Yld % | 1M Return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Ltd. | 1,922.10 | 4,61,169 | 41.97 | 5.17 | 0.72% | +9.22% |
| Cipla Ltd | 1,562.00 | 1,26,110 | 29.40 | 4.62 | 0.83% | +3.40% |
| Dr. Reddy's Laboratories Ltd | 1,278.50 | 1,06,680 | 19.20 | 3.74 | 0.62% | +2.10% |
Active Expiry: 2026-11-23 · Spot ₹1,922.10 · Max Pain ₹1,800.00
| Call OI | Call LTP | Strike (₹) | Put LTP | Put OI |
|---|---|---|---|---|
| 4.61L | ₹35.25 | 1860.00 | ₹25.50 | 3.48L |
| 3.59L | ₹25.15 | 1880.00 | ₹35.65 | 1.49L |
| 10.48L | ₹17.75 | 1900.00 | ₹47.80 | 1.23L |
| 1.39L | ₹12.05 | 1920.00 (ATM) | ₹62.10 | 1.00L |
| 1.53L | ₹8.45 | 1940.00 | ₹177.10 | 0.12L |
| 4.19L (Wall) | ₹5.85 | 1960.00 | ₹196.00 | 0.01L |
Curated Market Updates, Announcements & Sentiment
Board Meeting Intimation |Meeting Date: 14-Nov-2026
Board Meeting Intimation |Meeting Date: 14-Nov-2026
Newspaper Advertisement enclosed herewith.
Recording of Conference Call
Key Facts on Live NSE/BSE Price, Fundamentals, Shareholding & F&O Levels
Sun Pharmaceutical (SUNPHARMA) is currently trading at ₹1,922.10 (+3.34%) with a day range of ₹1,861.00 to ₹1,929.40 and a 52-week range of ₹1,583.70 to ₹2,046.90. On NSE (NSECM3351), LTP is ₹1,922.10; on BSE (BSECM524715), LTP is ₹1,922.00.
Sun Pharmaceutical Industries Ltd., founded in 1983, is India's largest pharmaceutical company and the fourth largest specialty generic pharmaceutical firm globally. Headquartered in Mumbai, it manufactures branded generics, pure generics, specialty products, and APIs across 43 facilities worldwide. The company serves over 100 countries, with around 70% of revenue from international markets, primarily the US and India. Key therapeutic areas include neuropsychiatry, cardiology, oncology, dermatology, and anti-infectives. Major acquisitions like Ranbaxy Laboratories in 2014 and Taro Pharmaceuticals have bolstered its position. It employs over 43,000 people and reported $6.3 billion in revenue for FY2024. In TTM, SUNPHARMA reported annual revenue (sales) of ₹61,631 Cr, operating profit of ₹18,064 Cr, and net profit of ₹10,987 Cr.
As of Sep 2026, Promoters hold 52.68% of SUNPHARMA, Foreign Institutional Investors (FIIs) hold 14.36%, Domestic Institutional Investors (DIIs) hold 22.27%, and Retail & Others hold 10.70%.
For the 2026-11-23 expiry, SUNPHARMA options show an ATM strike of ₹1,920.00, Max Pain at ₹1,800.00, major Put OI support at ₹1,800.00 (9,25,050 OI), and Call OI resistance at ₹1,960.00 (4,18,600 OI).